MediCare将为波立维的相关基因检测付费
时间：2013-05-14 10:21:38 来源：三济生物 点击：
NEW YORK (GenomeWeb News) – Transgenomic today announced it has received confirmation of Medicare coverage for its clopidogrel response test.
2012年7月24日，纽约，Transgenomic今天宣布，该公司已经收到MediCare将为氯吡格雷药物检测付费的通知。
National Government Services, the Medicare fiscal intermediary for Connecticut, has confirmed coverage for Transgenomic's Clopidogrel Genetic Absorption Activation Panel, or C-GAAP, providing 48 million Americans currently on Medicare access to the test, formerly called PGxPredict: Clopidogrel.
国家政府（医疗）服务局----NGS, 在康涅狄格州为MediCare提供财务管理，已经确认将覆盖氯吡格雷基因检测（C-GAAP，氯吡格雷基因-吸收活性委员会），将提供4800万美国人目前在MediCare接受医疗服务，能按需提供检测，以前称为“药物基因组学预测：氯吡格雷”
The saliva-based test identifies patients with mutations to their CYP2C19 and ABCB1 genes that cause them to incompletely absorb or activate clopidogrel, which also goes under the brand name Plavix. C-GAAP analyzes markers in both genes to identify those patients who are at genetically heightened risk for major adverse cardiovascular events because of diminished effectiveness of the drug.
通过检测口腔粘膜组织，能确定病人是否有CYP2C19和ABCB1的基因突变，导致他们对氯吡格雷不能完全吸收或活化。（氯吡格雷的商品名，也即波立维）。C-GAAP检测这两个基因标志物，能确定哪些患者由于基因因素，降低了药物的疗效，从而使主要心血管事件的危险升高。
According to Transgenomic about half of all patients on clopidogrel have markers in CYP2C19 or ABCB1 indicative of compromised absorption or activation of the drug. In 2010, the US Food and Drug Administration issued a "black box" warning to Plavix's label to highlight that patients with the CYP2C19*2/*2 genotype and treated with the drug exhibit higher rates of adverse cardiovascular events than patients with normal CYP2C19 function.
根据Transgenomic的消息，大约一半使用氯吡格雷的患者带有CYP2C19或ABCB1的非活性基因，使得吸收或药物代谢活化不能正常进行。2010年，美国FDA发布了针对波立维的“黑框警示”，警告CYP2C19*2/*2基因型的患者治疗时，比正常CYP2C19功能的患者，心血管事件的危险程度升高。
Craig Tuttle, CEO of Omaha, Neb.-based Transgenomic, called the Medicare decision a "major commercial milestone" for the firm "and an important step toward widespread use of C-GAAP. Medicare covers about 75 percent of patients for whom the test would be ordered and acceptance by the insurance program "removes a significant barrier for physicians and allows for a more rapid adoption of this important genetic test," he said.
CraigTuttle,Transgenomic公司的CEO认为，MediCare的这一决定是“非常关键的决策”，使“氯吡格雷基因-吸收检测，C-GAAP”得到广泛应用。在美国，MediCare为75%的人群提供医疗服务，这些人进行氯吡格雷基因检测，将获得医保报销支付。“这将去除医生关切的障碍，大大加速基因检测的接受度”。
2012年7月24日，纽约，Transgenomic今天宣布，该公司已经收到MediCare将为氯吡格雷药物检测付费的通知。
National Government Services, the Medicare fiscal intermediary for Connecticut, has confirmed coverage for Transgenomic's Clopidogrel Genetic Absorption Activation Panel, or C-GAAP, providing 48 million Americans currently on Medicare access to the test, formerly called PGxPredict: Clopidogrel.
国家政府（医疗）服务局----NGS, 在康涅狄格州为MediCare提供财务管理，已经确认将覆盖氯吡格雷基因检测（C-GAAP，氯吡格雷基因-吸收活性委员会），将提供4800万美国人目前在MediCare接受医疗服务，能按需提供检测，以前称为“药物基因组学预测：氯吡格雷”
The saliva-based test identifies patients with mutations to their CYP2C19 and ABCB1 genes that cause them to incompletely absorb or activate clopidogrel, which also goes under the brand name Plavix. C-GAAP analyzes markers in both genes to identify those patients who are at genetically heightened risk for major adverse cardiovascular events because of diminished effectiveness of the drug.
通过检测口腔粘膜组织，能确定病人是否有CYP2C19和ABCB1的基因突变，导致他们对氯吡格雷不能完全吸收或活化。（氯吡格雷的商品名，也即波立维）。C-GAAP检测这两个基因标志物，能确定哪些患者由于基因因素，降低了药物的疗效，从而使主要心血管事件的危险升高。
According to Transgenomic about half of all patients on clopidogrel have markers in CYP2C19 or ABCB1 indicative of compromised absorption or activation of the drug. In 2010, the US Food and Drug Administration issued a "black box" warning to Plavix's label to highlight that patients with the CYP2C19*2/*2 genotype and treated with the drug exhibit higher rates of adverse cardiovascular events than patients with normal CYP2C19 function.
根据Transgenomic的消息，大约一半使用氯吡格雷的患者带有CYP2C19或ABCB1的非活性基因，使得吸收或药物代谢活化不能正常进行。2010年，美国FDA发布了针对波立维的“黑框警示”，警告CYP2C19*2/*2基因型的患者治疗时，比正常CYP2C19功能的患者，心血管事件的危险程度升高。
Craig Tuttle, CEO of Omaha, Neb.-based Transgenomic, called the Medicare decision a "major commercial milestone" for the firm "and an important step toward widespread use of C-GAAP. Medicare covers about 75 percent of patients for whom the test would be ordered and acceptance by the insurance program "removes a significant barrier for physicians and allows for a more rapid adoption of this important genetic test," he said.
CraigTuttle,Transgenomic公司的CEO认为，MediCare的这一决定是“非常关键的决策”，使“氯吡格雷基因-吸收检测，C-GAAP”得到广泛应用。在美国，MediCare为75%的人群提供医疗服务，这些人进行氯吡格雷基因检测，将获得医保报销支付。“这将去除医生关切的障碍，大大加速基因检测的接受度”。
